MoonLake Immunotherapeutics' Sonelokimab's Phase 3 trials, PsA market growth, and Merck's $3B bid showcase potential. Read my ...

CHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response ...

In this era of decentralized finance, sharp investors and crypto whales are already loading up on Mutuum Finance (MUTM) tokens ahead of a massive price surge expected in 2025. The data from wallet ...

Phase III data presented at ASCO 2025 and published in The New England Journal of Medicine show that Pfizer’s Braftovi (encorafenib), combined with Erbitux (cetuximab) and mFOLFOX6, significantly ...

Amgen AMGN announced encouraging new data from its interim analysis of the global late-stage study evaluating Imdelltra ...

Poor investigator site selection remains a significant driver of spiraling costs and inefficiencies in clinical development.

LUND, SE / ACCESS Newswire / June 3, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - Spago Nanomedical AB (publ) ...

As criminal organizations expand their use of information technology, the frequency of global financial fraud rises to ...

Funding, Data and Resiliency Needed for Electric School Bus Success School Transportation News Special Reports ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...

EVP, Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS | Embrace the transformative power of multimodal ...